Announcements Trials
Browse Landscape

Status

Available 1Approved for marketing 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 10Expanded_access 2Observational 1

Sponsor

Cancer Type

Endocrine 2CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 32Multiple Myeloma 26Neoplasms 25Recurrence 23Melanoma 19Leukemia, Myeloid, Acute 16Breast Neoplasms 15Prostatic Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lung Neoplasms 9Ovarian Neoplasms 8Lymphoma 8Glioma 8Colorectal Neoplasms 8Small Cell Lung Carcinoma 7Lymphoma, Large B-Cell, Diffuse 7Carcinoma, Renal Cell 7Lymphoma, Non-Hodgkin 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Gastrointestinal Stromal Tumors 6Cholangiocarcinoma 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Neoplasm Metastasis 5Leukemia, Lymphocytic, Chronic, B-Cell 5Thyroid Neoplasms 4Lymphoma, Mantle-Cell 4

Interventions

3-Iodobenzylguanidine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Paraganglioma × Clear all
NCT01590680 2023-02-28

Expanded Access Protocol Using 131I-MIBG

Jubilant DraxImage Inc.

Available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT02961491 2019-01-30

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Approved for marketing
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡